- Home
- NEN vs CTNM Comparison
NEN vs CTNM Comparison
Compare NEN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- CTNM
- Stock Information
- Founded
- NEN 1977
- CTNM 2009
- Country
- NEN United States
- CTNM United States
- Employees
- NEN N/A
- CTNM N/A
- Industry
- NEN Building operators
- CTNM
- Sector
- NEN Real Estate
- CTNM
- Exchange
- NEN Nasdaq
- CTNM Nasdaq
- Market Cap
- NEN 250.0M
- CTNM 248.7M
- IPO Year
- NEN N/A
- CTNM 2024
- Fundamental
- Price
- NEN $71.05
- CTNM $11.70
- Analyst Decision
- NEN
- CTNM Strong Buy
- Analyst Count
- NEN 0
- CTNM 5
- Target Price
- NEN N/A
- CTNM $22.20
- AVG Volume (30 Days)
- NEN 824.0
- CTNM 113.0K
- Earning Date
- NEN 01-01-0001
- CTNM 11-05-2025
- Dividend Yield
- NEN 6.76%
- CTNM N/A
- EPS Growth
- NEN 34.86
- CTNM N/A
- EPS
- NEN 4.59
- CTNM N/A
- Revenue
- NEN $83,884,808.00
- CTNM N/A
- Revenue This Year
- NEN N/A
- CTNM N/A
- Revenue Next Year
- NEN N/A
- CTNM N/A
- P/E Ratio
- NEN $15.48
- CTNM N/A
- Revenue Growth
- NEN 4.96
- CTNM N/A
- 52 Week Low
- NEN $68.41
- CTNM $3.35
- 52 Week High
- NEN $84.00
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- NEN 44.84
- CTNM 53.50
- Support Level
- NEN $71.05
- CTNM $11.56
- Resistance Level
- NEN $73.50
- CTNM $12.87
- Average True Range (ATR)
- NEN 0.55
- CTNM 0.84
- MACD
- NEN -0.02
- CTNM -0.07
- Stochastic Oscillator
- NEN 0.00
- CTNM 44.59
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.